Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients

Date

07 Oct 2016

Session

Immunotherapy of cancer

Presenters

Miguel Sanmamed

Citation

Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378

Authors

M.F. Sanmamed1, J.L. Perez-Gracia2, J.P. Fusco2, C. Oñate3, G. Perez3, C. Alfaro3, S. Martín-Algarra2, A. González4, M.E. Rodriguez-Ruiz3, M.P. Andueza2, J. Wang1, A. Bacchiocchi5, R. Halaban5, H. Kluger6, M. Sznol6, I. Melero3

Author affiliations

  • 1 Immunobiology, Yale School of Medicine, 06511 - New Haven/US
  • 2 Medical Oncology, Clinica Universitaria de Navarra, 31008 - Pamplona/ES
  • 3 Laboratory Of Immunology, Universidad de Navarra, 31009 - Pamplona/ES
  • 4 Biochemistry, Clinica Universitaria de Navarra, 31008 - Pamplona/ES
  • 5 Dermatology, Yale School of Medicine, 06511 - New Haven/US
  • 6 Medical Oncology, Yale School of Medicine, 06511 - New Haven/US
More

Resources

Reserved to ESMO members
View the presentation

Background

Anti-PD-1 blockade effectively treats several tumor types. Yet, surrogate biomarkers of clinical benefit are needed to evaluate efficacy, given the delay in observing responses and the existence of pseudo-progressions. This work aims to evaluate serum IL8 levels as a biomarker during anti-PD-1 mAb treatment of melanoma and non-small cell lung cancer (NSCLC) patients.

Methods

44 metastatic melanoma and 19 metastatic NSCLC patients treated with anti-PD-1 mAb therapy as a single-agent, or in combination with anti-CTLA-4 mAb, were studied. Blood was withdrawn at baseline, 2-4 weeks after starting treatment, at best response and at disease progression. Serum IL8 levels were determined by sandwich ELISA. Wilcoxon test was used to compare changes in serum IL8 levels during treatment and the Mann-Whitney U test was used to assess strength of correlation between serum IL8 levels and clinical response assessed by RECIST 1.1 criteria.

Results

The discovery set consisted of 12 melanoma patients treated with anti-PD-1 mAb. In responding patients, serum IL8 levels decreased significantly at the moment of BR compared to baseline levels, and significantly increased upon progression. In non-responders, IL8 levels significantly increased at the moment of progression compared to baseline levels (Table 1). These results were confirmed in a validation set of 17 melanoma and 19 NSCLC patients similarly treated with anti-PD-1 mAbs (Table 1). Additionally, we observed that early changes in serum IL8 levels (2-4 weeks after treatment initiation) strongly correlate with response in the melanoma discovery set (p = 0.05), melanoma validation set (p = 0.001), NSCLC set (p = 0.001) and in a group of 15 melanoma patients treated with anti-CTLA-4 in combination with anti-PD-1 mAbs (p = 0.001).

Responders (clinical setting) Baseline M (Q1-Q3) pg/ml Best response M (Q1-Q3) pg/ml p (baseline vs best response) Progression M (Q1-Q3) pg/ml p (best response vs progression)
Melanoma (discovery set) 43.7 (36-49) 13.6 (5-19)

Conclusions

Changes in serum IL8 levels might be used to monitor and predict response to anti-PD-1 therapy in metastatic melanoma and NSCLC patients.

Clinical trial identification

NOT APPLICABLE

Legal entity responsible for the study

Clinica Universidad de Navarra and Yale University

Funding

Gobierno de Navarra Salud, EU comission IACT and PROCRP, MINECO (SAF2008-03294, SAF2011-22831)

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.